Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells

T Chano, K Mori, K Scotlandi, S Benini… - Oncology …, 2004 - spandidos-publications.com
T Chano, K Mori, K Scotlandi, S Benini, C Lapucci, MC Manara, M Serra, P Picci, H Okabe…
Oncology reports, 2004spandidos-publications.com
Multidrug resistance (MDR) to anticancer agents is a major barrier to the successful
treatment of human osteosarcomas. Current understanding of the genes that contribute to
the features of MDR is limited, and the mechanisms remain unclear. Here we applied
differential display reverse transcription-polymerase chain reaction (DDRT-PCR) to parental
and MDR-variants of U-2 OS human osteosarcoma cells, to clarify the genes involved in the
MDR cells, and identified five candidate genes. These are BCRP (breast cancer resistance …
Abstract
Multidrug resistance (MDR) to anticancer agents is a major barrier to the successful treatment of human osteosarcomas. Current understanding of the genes that contribute to the features of MDR is limited, and the mechanisms remain unclear. Here we applied differential display reverse transcription-polymerase chain reaction (DDRT-PCR) to parental and MDR-variants of U-2 OS human osteosarcoma cells, to clarify the genes involved in the MDR cells, and identified five candidate genes. These are BCRP (breast cancer resistance protein) encoding a transmembrane efflux pump; RB1CC1 (RB1-inducible coiled-coil 1), a tumor suppressor regulating RB1 (retinoblastoma 1) expression; a novel transcriptional variant of dUTPase; SSR2 (β-signal sequence receptor), which is associated with protein translocation across ER membrane; and HSP105 encoding high molecular mass heat shock proteins. Molecular and biological characterization of these genes will yield further insight into the features between MDR and tumor progression in human osteosarcomas.
Spandidos Publications